Skip to content

Silicium resorption out of Equisetum arvense compoundings – A randomised, active controlled pilot study

Silicium resorption out of Equisetum arvense compoundings – A randomised, active controlled pilot study - /

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
DRKS
Registry ID
DRKS00016628
Enrollment
12
Registered
2019-02-04
Start date
2019-02-08
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

Group 1: Group 1: Four subjects belong to the control group. They ingest between 9:30-10:00 a clock on the day of the baseline assay and on the both following days at the same time 1000 mL silicon con

Sponsors

Uni-Zentrum Naturheilkunde / Institut für Infektionsprävention und KrankenhaushygieneUniversitätsklinikum Freiburg
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: In the study healthy, male adults aged between 18 and 60 years, deciding self-determined about their attendance participate.

Exclusion criteria

Exclusion criteria: - acute or chronic diseases of every kind (except for hay fever) - regular intake of any drugs or medications (incl. herbal and homeopathic drugs) - drug addiction within the last year before start of the study - participation in another study within the last four weeks before start of the study - blood donation during the three weeks before the first pre-examination - insuffitient language skills to understand the subject information script

Design outcomes

Primary

MeasureTime frame
Maximal silicon blood plasma level after the intake of TEA with 3000 mg/L silicon (group 3) compared to si-water with 300 mg/L silicon (group 1).

Secondary

MeasureTime frame
-Maximal silicon blood plasma level after intake of TEA with 300 mg/L (group 2) -Tolerability of TEA compounding on a numeric rating scale from 0 (very bad) to 10 (very good) on day three of ingestion -Kinetic: -course of silicon concentration in blood serum and urine -Safety: -the safety will be examined based on undesirable events with the evaluation of causality -The following laboratory parameters will be examined: -Blood values: -differential blood count, differentiation of lymphocytes, proliferation of t-cells out of EDTA-blood -kidney values: -creatinine and urea in blood serum -liver values: -GOT, GPT, ?-GT in blood serum

Countries

Germany

Contacts

Public ContactAljoscha Waterstradt

Uni-Zentrum Naturheilkunde / Institut für Infektionsprävention und Krankenhaushygiene Universitätsklinikum Freiburg

aljoscha.waterstradt@uniklinik-freiburg.de0761/270-82010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 14, 2026